



```

101 TAGGGACACGACAGACAGATAGTGTGCTGTCCTCCAGCAAAATATATC 150
|||||
34 euGlyAspArgGluTyrAsnArgAspSerValCysProGlnGlyTyrIle 50
|||||
151 CACGCTCAAAATAAATGCAATTCGTGTACCAAGTCCACAAAGAACCTA 200
|||||
51 HisProGlnAsnAsnSerIleCysCysThrIleCysHisIleGlyThr 67
|||||
201 CTGTGTAATGACTGTCTCAGGCTGGGAGGATACGACTGACGAGACT 250
|||||
67 IleuLysAsnAspCysProGlnGlyGlnAspThrAspCysArgGlnC 84
|||||
251 GTACAGCGGCTGCTTCACGCTTCAGAAACACACCTACACACTGCTTC 300
|||||
84 ysGluSerGlySerPheThrAlaSerGlnAsnHisLeuArgHisCysLeu 100
|||||
301 ACCGCTCCAAAATGCTCAAGAAATGGGTGACGTCGAGATCTCTCTTC 350
|||||
101 SerCysSerIleCysAsnArgCysGlnMetGlyGlnValGlnIleSer 117
|||||
351 CAAATGGACGGGACACGCTGTGTGCTGCTGACAGCAAGAACACAGTAC 400
|||||
117 sThrValAspArgAspThrValCysGlyCysArgGlyAsnGlnIleYrArg 134
|||||
401 ATATATGACAGTGAATATCTTTTCCAGTGTTCATTCGACGCCCTCTCC 450
|||||
134 IstYrTrpSerGlnAsnLeuPheGlnCysPheAsnCysSerLeuCysLeu 150
|||||
451 AARGGATCGTGCACCTCTCTGCTGACAGCAAAACACACACCTGTCAC 500
|||||
151 AsnGlyThrValHisLeuSerCysGlnGlnGlySerHisAsnThrValCys 167
|||||
501 CTGCTATGCAAGTTCTTCTTAGCAAAAGATGTGTGCTGCTAGTGA 550
|||||
167 rCysHisAlaIlePhePheLeuArgGlnAsnGlnCysValSerCysSer 184
|||||
551 ACTGTAAAGAAAGCTGACATGCTACCAAGTGTGCTGCTGCTGCTGCT 600
|||||
184 SerGlySerSerSerSerSerSerSerSerSerSerSerSerSerSer 200
|||||
601 AAGCTAAGGCGACCTGACGATTCAGCACACACACACACACACACAC 650
|||||
201 AsnValCysGlyThrGlnAspSerGlyThrThrValLeuLeuProLeu 217
|||||
651 CATTTCTTTGCTTTGCTTTTATGCTTCTGCTGCTGCTGCTGCTGCT 700
|||||
217 tLeuPhePheGlyLeuCysLeuLeuSerLeuLeuPheIleGlyLeuMet 234
|||||
701 ATGCTTACCAACGCTGCAAGTGTCAAGCTGCTGCTGCTGCTGCTGCT 750
|||||
234 YrArgTyrGlnArgTrpLysSerLysLeuTyrSerIleValCysGlyLys 250
|||||
751 TACACATTCAGAAACAGGCGACCTTGAAGCAACACACTACTAAGCCCT 800
|||||
251 SerThrProLeuLysGlnGlyLeuLeuGlnGlyThrThrThrLysProLe 267
|||||
801 GGGCGCAAAACCAAGCTTATGCTGCTGCTGCTGCTGCTGCTGCTGCT 850
|||||
267 GAlaProAsnProSerPheSerThrThrProGlyPheThrProThrLeuG 284
|||||
851 GCTTCAGTTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
|||||
284 YrPheSerProValProSerSerThrPheThrSerLysLysThrIleThr 300
|||||
901 CCGCGTGATGTCCTCAACTTTCGGGCTTCGGGCTGACAGAGTGGACAC 950
|||||
301 ProGlyAspCysProAsnPheAlaIleProArgArgGlnValAlaProbr 317
|||||
951 CTATCAGGGGCTGACCTCATCTTGGGATAGGCTGCTGCTGCTGCTGCT 1000
|||||
317 CysGlnGlnGlnAlaAspProGlnGlnAlaThrAlaGlnAlaSerAsp 334

```

```

1001 TCCCAAAATCCCTTCAGAAATGGGAGGACAGGCGCCCAAGCCACAGAGC 1050
|||||
334 leProAsnProLeuGlnLysTrpGluAspSerAlaHisLysProGlnSer 350
|||||
1051 CTAGACACTGATGACGCGCGGACGCTGTACGCTGTGGTGAATATGCTCC 1100
|||||
351 leuAspThrAspAspProAlaThrLeuLysAlaValValGluAsnValP 367
|||||
1101 CCGCTTGGCTGCAAGAAATGCTGCGGCTGCTAGGCTGAGACACAGC 1150
|||||
367 obProLeuArgTrpLysGluPheValIleArgLeuGlyLeuSerAspHisG 384
|||||
1151 ACATCATGCTGCTGACGCTGCAAGACGCGGCTGCTGCTGCGGAGCGCAA 1200
|||||
384 luIleAspArgLeuGlnLeuGlnAsnGlyArgCysLeuArgGlnAlaGln 400
|||||
1201 TACAGCATGCTGAGAACCTGAGAGGAGGACAGAGCGGAGGAGAGGAC 1250
|||||
401 TyrSerMetLeuAlaThrTrpArgArgGlyThrProArgGlnAlaThr 417
|||||
1251 GCTGAGATGCTGGTAAACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1300
|||||
417 rleuGlnLeuLeuGlyArgValLeuArgAspMetAspLeuLeuGlyCysL 434
|||||
1301 TCGACGACATCGACGCGCTTTCGCGCGCGCGCGCGCTGCGCGCGCGCG 1350
|||||
434 euGlnAspIleGlnAlaLeuCysGlyProAlaAlaLeuProProAla 450
|||||
1351 CCGAGCTCTCTCAGA 1365
|||||
451 ProSerLeuLeuArg 455

```

seq\_name: /SIBS2/qcdata/geneseq/geneseq/AA1993.DAT.AAB42054

seq\_documentation\_block:

AA42053 standard, protein; 455 AA.

AA42059;

29-APR 1994 (first entry)

Lambda derived TNF-R.

Human; tumour necrosis factor receptor; TNF-R; interleukin-1 receptor;  
IL-1R; fusion protein; linker; TNF; IL-1; cachexia; cerebral malaria;  
rheumatoid arthritis; diabetes; multiple sclerosis; septic shock;  
pulmonary fibrosis; silicosis; allograft; xenograft; rejection;  
graft versus host disease; sepsis; inflammation; allergy;  
autoimmune dysfunction.

Homo sapiens.

Lambda-9110-7clutlp.

Key Location/Qualifiers

Peptide 1..40

/note= "Signal peptide"

Protein 41..455

/note= "Mature TNF-R"

W09319777-A.

14-OCT-1993.

26-MAR-1993; 9405 DS02938.

30-MAR-1992; 9205-0860710.

(IMMUNEX CORP.

Smith CA;

W01, 1993 37652/42.

N-PSDB; AAO49932.

XX New fusion protein tumour necrosis factor and human interleukin-1  
 PT receptor - useful in therapy, diagnosis and assays of e.g.  
 PL rheumatoid arthritis, diabetes, cerebral malaria, sepsis, etc.  
 XX Disclosure: Page 57-59; 85pp; English.  
 XX The sequences given in AAK42058-59 represent human tumour necrosis  
 factor receptor (TNF-R) and the sequences in AAK42059-61 represent  
 human interleukin-1 receptor (IL-1R). These sequences were used in  
 CC the production of a fusion protein which conformed to one of the  
 CC formulae:  
 CC TNF-R-linker-TNF-R-linker-IL 1R  
 CC IL-1R-linker-TNF-R-linker-TNF-R or  
 CC TNF-R-linker-TNF-R  
 CC The linker may comprise 5-100 amino acids selected from Gly, Asp,  
 CC Ser, Thr and Ala. These linkers separate the individual moieties  
 CC by such a distance that each component of the fusion protein is  
 CC capable of folding into the secondary or tertiary structure required  
 CC for its biological activity. These fusion proteins may be used in  
 CC therapy, diagnosis and assays for conditions mediated by TNF or IL-1,  
 CC particularly in conditions in which both TNF and IL-1 play a causative  
 CC role. They may be used to treat cachexia, rheumatoid arthritis,  
 CC diabetes, multiple sclerosis, pulmonary fibrosis and silicosis,  
 CC cerebral malaria, allograft and xenograft rejection in graft verses  
 CC host disease, sepsis, septic shock, inflammation, allergies and  
 CC autoimmune dysfunction.  
 XX  
 XX Sequence 455 AA:

alignment\_scores:  
 Quality: 2497.00 Length: 455  
 Ratio: 5.466 Gaps: 0  
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment block:

US-09-525-998a-1 x AAK42059

Align seq 1/1 to: AAK42059 from: 1 to: 455

1 ATGGGCGCTTTCAGCGGCGCTTGAAGTGTGCTGGCAATGGGCTGCTGGA 50  
 1 MetGlyLeuSerThrValProAspLeuLeuLeuProLeuValLeuLeuG 17  
 51 GGTGTGGTGGCAATATACCGCTCAGCGGCTATTGGACTGCTGCTCCACC 100  
 17 LeuLeuValGlyTleTyrPheSerGlyValIleGlyLeuValProHisL 34  
 101 TAAAGGACAGGAGAAAGAGATATGTGTGTGCTCCCAAGGAAATATATC 150  
 34 GlnGlyAspArgGlnGlySerValcysProGlnGlyIleTyrTle 50  
 151 CAGCTCTCAAAATATTCGATTGTGTACCAAGTGGCAACAAAGAAACTA 200  
 51 HisProGlnAsnSerIleGlySerThrIleGlySerGlyValIleSerGly 67  
 201 CTGGTACAAATGACGTGACAGCGCGCGGCGGACGATACCGATTCAGGAG 250  
 67 IleuTyrAsnAspCysProGlyProGlyGlnAspThrAspCysArgGlnC 84  
 251 GTGAGAGAGAGTGTCTTCAAGCGTTTCAGAAACAAACATCAGACATCTG 300  
 84 PheGluSerGlySerPheThrAlaSerGluAsnHisGlnArgHisCysGlu 100  
 301 AGCTGCTCCAAATGCGCAAGAAAGAAATGGGTGAGTGGAGATCTCTTGTG 350  
 101 SerGlySerLeuGlySerMetTyrGlnLeuGlyGlnValIleSerSerGly 117  
 351 CACAGTGGACCGGACACCGGAGTGGTGGTGGTGGTGGTGGTGGTGGTGG 400  
 117 SThrValAspArgAspThrValcysGlyCysArgTleGlyAsnGlnTyrArg 134

401 ATTATTCAGTGAAGAAAGCTTTTTCAGTGG 450  
 134 AspThrSerGluAsnLeuPheLeuTyrGlnAspCysSerThrGlySer 150  
 451 AATGGGACGCGGTCACGCTTTCGCTAGTATAAAGACATAAATGCTGAA 500  
 151 AsnGlyThrValHisLeuSerGlyThrGlyLeuAsnThrValTyrSer 167  
 501 TGGGAG 550  
 167 TcysHisAlaGlyThrPheGluArgThrGlnAsnGlyCysValSerGlySer 184  
 551 ACTGTAAAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 600  
 184 SerCysTyrSerLeuThrCysThrThrThrThrThrThrThrThrThr 200  
 601 AATGTTAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 650  
 201 AsnValGlyGlyThrGlnAspSerGlyThrThrValLeuLeuLeuLeu 217  
 651 CATTTTCTTGGCTTTTGGCTTTTGGCTTTTGGCTTTTGGCTTTTGGCT 700  
 217 ThrPheThrGlyThrGlySerLeuLeuSerLeuLeuLeuLeuLeuLeu 234  
 701 ATGGTAAAG 750  
 234 TyrArgThrAlaGlnTyrGlySerGlySerThrValGlyGlyGly 250  
 751 CGGACACCTTAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 800  
 251 SerThrThrGlnGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGly 267  
 801 GCGGCAAAATCAAGCTTACGTCGCTACGCTACGCTACGCTACGCTACG 850  
 267 GlnArgAsnSerSerPheSerProThrProGlyGlyLeuThrProLeu 284  
 851 GCTTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900  
 284 TyrSerProValProSerSerThrThrThrThrThrThrThrThrThr 400  
 901 GCGGCTACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 950  
 301 ProGlyAspGlySerAsnProAlaAlaProArgArgArgValAlaPro 317  
 951 CTATCAGCGGCTGACCGCAACCTTGGCAAGCGCTGCTGCTGCTGCTGCT 1000  
 317 GlnTyrGlyAlaAspThrThrLeuAlaThrAlaLeuAlaSerAspPro 334  
 1001 TCGGCAAG 1050  
 334 LeuProAsnProGlnGlyThrPheAspSerAlaHisTyrSerGlnSer 350  
 1051 CTATCAGCTGACGACGCGCGGACGCTGTAAGCTGCGGAGAGAGAGAG 1100  
 351 LeuAspThrAspAspProAlaThrLeuAlaValValAlaAspValThr 467  
 1101 CCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1150  
 367 GProLeuArgThrGlySerLeuThrValThrArgGlnGlyLeuSerAspHis 484  
 1151 AGATGTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200  
 484 ThrThrAspArgGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGln 400  
 1201 TACAG 1250  
 401 TyrSerMetLeuAlaThrThrArgArgArgArgArgArgArgArgArg 417  
 1251 GCTGGAG 1300  
 417 ThrGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGln 434  
 1301 TGGAG 1350













```

|||||
301 ProGlyAspCysProAsnPheAlaAlaProArgArgGluValAlaProPr 317
951 CTATACAGCGGCTCAGCCCAATCTTGGGACAGCGGCGGCGGACGCCA 1000
317 GyrGlnGlyAlaAspProIleLeuAlaThrAlaLeuAlaSerAspProI 334
1001 TCTTCAATCTTCTTCAAGAGTGGAGAGCAACGGGCTCAAAACACAGAGC 1050
334 LeProAsnProGlnGlnLysIlePheAspSerAlaHisLysProGlnSer 350
1051 CTAGACATCTGATGACCGGAGAGGCTGATGATGATGATGATGATGATG 1100
351 LeuAspThrAspAspProAlaThrLeuTyrAlaValValGluAsnValPr 367
1101 CCGCTTCTGCTCTCAAGCAATCTTCTGCGGCGGCTGAGGCTGAGGCTG 1150
367 GProLeuAlaThrPheGlyPheValAlaGlnGlnGlnLeuSerAspHisG 384
1151 ACATGGATGGCTGATCTTCTTCAACAGGCTGCTTCTTCTTCTTCTTCT 1200
384 TulleAspArgGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGln 400
1201 TACAGCATGCTGAGAGCTTCTTCAAGAGAGAGAGAGAGAGAGAGAGAG 1250
401 TyrSerMetLeuAlaThrTrpArgArgArgThrProArgArgGluAlaTh 417
1251 GCTGACAGCTGCTGGGACAGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1300
417 rLeuGlnLeuLeuGlyArgValLeuArgAspMetAspLeuLeuGlyCysL 434
1301 TGAAGCAATCTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1350
434 euGluAspIleGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGln 450
1351 CCCAGCTTCTTCAGA 1365
451 ProSerLeuLeuArg 455
seq.name: /S09-525-998a-1.rag:seq:1:pro:seq:/AA26984:1:1:AA26984
seq_documentation_block:
ID AAB26984 standard; Protein: 455 AA.
XX
AC AAB26984:
XX
DI 02-FEB-2001 (first entry)
XX
DE Human TNFR 1.
XX
KW Human; TNFR 1; tumor necrosis factor; TR9 receptor; immunosuppressive;
KW antiinflammatory; cardiac; antiasthmatic; antidiabetic; antiallergic;
KW antithrombotic; antirheumatic; anti-HIV; anticonvulsant; cytostatic;
KW neuroprotective; gene therapy; Death Domain Containing Receptor 6;
KW common variable immunodeficiency; X-linked agammaglobulinemia;
KW severe combined immunodeficiency; Wiskott-Aldrich syndrome;
KW autoimmune disease; rheumatoid arthritis; allergic encephalomyelitis;
KW multiple sclerosis; diabetes mellitus; asthma; epilepsy; cancer;
KW cardiovascular disease; neurological disease; protein coordinate data.
XX
OS Homo sapiens.
XX
UN W0200056862-A1.
XX
PD 28-FEB-2000.
XX
PF 16-MAR-2000; 2000W0-0509831.
XX
PK 24-MAR-1999; 99US-0126019.
XX
PR 14-MAY-1999; 99US-0134220.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX

```

```

PI Ni J, Gentz RL, Yu G, Fan P;
DR WPI; 2000-594575/56.
XX
XX Nucleic acid molecule encoding a human tumor necrosis factor receptor,
XX known as TR9, useful for treating, preventing and diagnosing severe
XX combined immunodeficiency, autoimmune diseases, HIV infection, epilepsy
XX and cancer.
XX
XX Discl:5980, Fig 2, 220pp; English.
XX
XX The present sequence is TNFR 1, a member of the tumor necrosis factor
XX receptor family. A novel human tumor necrosis factor receptor,
XX designated TR9, has been isolated. The TR9 receptor is also known as
XX Death Domain Containing Receptor 6. TR9 polypeptides, polynucleotides or
XX analogs are useful for treating, preventing or diagnosing common
XX variable immunodeficiency, X-linked agammaglobulinemia, severe combined
XX immunodeficiency and Wiskott-Aldrich syndrome, autoimmune diseases (such
XX as rheumatoid arthritis, allergic encephalomyelitis, multiple sclerosis,
XX diabetes mellitus and asthma), HIV infection, epilepsy, cancer,
XX cardiovascular diseases and other neurological diseases.
XX
S0 Sequence 455 AA:

alignment_scores:
    Quality: 2487.00      Length: 455
    Ratio: 5.466         Gaps: 0
    Percent Similarity: 100.000      Percent identity: 100.000

alignment_block:
09-00-525-998a-1 x AAB26984

Align seq 1/1 to: AAB26984 from: 1 to: 455

1 ATGGGCTCTCTGACGCTGCTTCAATCTTCTGCTGCAACAGAGCTGCTGGA 50
|||||
1 MetGlyLeuSerThrValProAspLeuLeuLeuLeuProLeuValLeuLeuG 17
|||||
17 uLeuLeuValGlyIleTyrProSerGlyValIleGlyLeuValProHisL 34
|||||
101 TAGGGCAACAGAGAGAGAGAGATAGTGTGTGTGTGTGTGTGTGTGTGT 150
|||||
34 euGlyAspArgGlnGlyArgAspSerValCysProGlnGlyLysTyrIle 50
|||||
151 CACCGCTCAAAATATATCGATTGCTTCAACAGTGTGCAACAGAGCTCA 200
|||||
51 HisProIleuAsnSerIleCysCysThrLysCysHisLysGlyThrTy 67
201 CTGTCTCAATATCTCTGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 250
|||||
67 rLeuTrpAsnAspGlySerGlnGlnGlnGlnGlnGlnGlnGlnGlnGln 84
|||||
251 GTAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 300
|||||
84 YSerGlnSerGlySerProThrAlaSerGlnAspHisGlnGlnGlnGln 100
301 AGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 350
|||||
101 SerCysSerLysCysArgLysSerGlnGlnGlnGlnGlnGlnGlnGln 417
|||||
351 CACAGTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 400
|||||
117 sThrValAspArgAspThrValCysGlyCysArgLysAsnGlnTyrArgH 134
401 ATTATTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 450
|||||
134 isTyrTrpTrpGluAsnGlnProGlnCysPheAspCysSerLeuGlySer 150
|||||
451 AATGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 500
|||||

```























```
|||||
117 subrValAspArgAspThrValCysGlyCysArgLysAsnGlnIleTyrArgH 134
401 ATTATGTAGAGTGAACAACTTTTCTCAGTGTTCATATGAGAGCTCTGCTC 450
|||||
134 IsIyrTrpSerGlnAsnLeuPheGlnCysPheAsnCysSerIleuCysIleu 150
451 AATGGCAGCTGTCACCTCTCTCTGGCAGCAGAAACAGAACACCCGTGTGCAC 500
|||||
151 AsnAlaThrValHisLeuSerCysGlnGlnLysGlnAsnThrValCysTh 167
500 CAGCCACACACAGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 550
|||||
167 rCysHisAlaGlyPhePheLeuArgGluAsnGluCysValSerCysSerA 184
551 ACTGTAGCAAAAGCTGTGAGTGTGAGTGTGCTTACCCACAGATGAG 600
|||||
184 snCysLysLysSerLeuGlnLysThrLysLysLysLysLysLysLysLysLys 200
601 AATGTTAAGCCATTCAGTCTCAGTCTCAGTCTCAGTCTCAGTCTCAGTCTC 650
|||||
201 AsnValLysGlyThrGluAspSerGlyThrThrValLeuLeuProLeuVa 217
651 CATTTTCTCTGGCTTTGGCTTTTATCCCTCTCTCTCTCTCTCTCTCTCTCTCT 700
|||||
217 ILePhePheGlyLeuCysLeuLeuAlaLeuPheIleGlyLeuMetT 234
701 ATGCTACCAAGGTGAAATGCAAGTCTACTGCTCTCTCTCTCTCTCTCTCTCT 750
|||||
234 yTArgTyrCLeuArgLysSerLysLeuLysSerLysValLeuValCysGlyLys 250
751 TCGCACCTGAAAGAGAGGGGAGCTTCAAGCACTACTACTACTACTACTACTACT 800
|||||
251 SerThrProGluLysGluGlyLeuLeuGluGlyThrThrThrLysProLe 267
801 GATCCCAAAACCACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 850
|||||
267 uAlaProAsnProSerPheSerProThrProGlyPheThrProThrLeuG 284
851 GTTTCAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
|||||
284 yPheSerProValProSerSerThrPheThrSerSerSerThrThrThr 300
901 CCGCGGACATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 950
|||||
301 ProGlyAspCysProAsnPheAlaAlaProArgArgGluValAlaProPr 317
951 CTATCAGGGGCTGACCCCATGCTGCGACAGCCCTGGCTGGCGAGCCCA 1000
317 GlyGlnGlyAlaAspProIleLeuAlaThrAlaLeuAlaSerAspProI 334
1001 TCGCCAAAGGCTTCAAAATGAAAGAA'AAAGAA'AAAGAA'AAAGAA'AAAG 1050
|||||
334 LeProAsnProLeuGlnLysTrpGluAspSerAlaHisLysProGlnSer 350
1051 CTACACATCTGACCTGGCCAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1100
|||||
351 LeuAspThrAspAspProAlaThrLeuTyrAlaValValGluAsnValPr 367
1101 CCGCTTGGCTGGAGGAAATTCCTGGCGGCGCTAGGCTCAGCGACCCACG 1150
|||||
367 GlyLeuArgTrpLysGlnPheValArgArgLeuGlyLeuSerAspHisG 384
1151 AGATGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1200
|||||
384 IuIleAspArgLeuGlnLeuGlnAsnGlyArgCysLeuArgGluAlaGln 400
1201 TACACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1250
|||||
401 TyrSerMetLeuAlaThrIleArgArgArgThrProArgArgGluAlaTh 417
1251 GCTTCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1300
|||||
```

```
417 rIeuGlnIleuLeuGlyArgValLeuArgAspMetAspLeuLeuGlyCysL 434
1301 TGGAGAGAA'AT'GAAAGAAAGAA'ATTGGAGAGAGAGAGAGAGAGAGAG 1350
|||||
434 euGluAspIleGluGluAlaLeuCysGlyProAlaAlaLeuProProAla 450
1351 CCCAGTCTCTCACA 1365
|||||
451 ProSerLeuLeuArg 455
```



